Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zura Bio Limited - Class A Ordinary shares
(NQ:
ZURA
)
5.160
+0.040 (+0.78%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zura Bio Limited - Class A Ordinary shares
< Previous
1
2
Next >
Zura Bio Reports Business Updates and Outlook for 2026
January 12, 2026
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
November 13, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 20, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
August 14, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2025
From
Zura Bio
Via
Business Wire
Zura Bio Announces Chief Financial Officer Transition
July 01, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present at the Jefferies Global Healthcare Conference
May 27, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
May 20, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
May 08, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
March 25, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
February 24, 2025
From
Zura Bio Limited
Via
Business Wire
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
December 23, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
November 14, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
November 07, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Participate in Two Upcoming Investor Conferences in November
October 30, 2024
From
Zura Bio
Via
Business Wire
Zura Bio to Present at Three Upcoming Investor Conferences in September
September 03, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants
August 12, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants
August 09, 2024
From
Zura Bio Limited
Via
Business Wire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
July 12, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
June 14, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
June 06, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
June 03, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Participation in June Investor Conferences
May 29, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
April 18, 2024
From
Zura Bio
Via
Business Wire
Zura Bio Announces Robert Lisicki as CEO and Director
April 08, 2024
From
Zura Bio Limited
Via
Business Wire
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
March 28, 2024
From
Zura Bio Limited
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
